Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Capital Expenditures (2016 - 2018)

Historic Capital Expenditures for Syndax Pharmaceuticals (SNDX) over the last 4 years, with Q4 2018 value amounting to $14000.0.

  • Syndax Pharmaceuticals' Capital Expenditures fell 6666.67% to $14000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $187000.0, marking a year-over-year increase of 9081.63%. This contributed to the annual value of $129000.0 for FY2021, which is N/A changed from last year.
  • As of Q4 2018, Syndax Pharmaceuticals' Capital Expenditures stood at $14000.0, which was down 6666.67% from $173000.0 recorded in Q1 2018.
  • In the past 5 years, Syndax Pharmaceuticals' Capital Expenditures registered a high of $173000.0 during Q1 2018, and its lowest value of $1000.0 during Q3 2017.
  • Over the past 4 years, Syndax Pharmaceuticals' median Capital Expenditures value was $42000.0 (recorded in 2017), while the average stood at $59444.4.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Capital Expenditures surged by 32307.69% in 2016, and later tumbled by 9818.18% in 2017.
  • Quarter analysis of 4 years shows Syndax Pharmaceuticals' Capital Expenditures stood at $31000.0 in 2015, then soared by 77.42% to $55000.0 in 2016, then decreased by 23.64% to $42000.0 in 2017, then tumbled by 66.67% to $14000.0 in 2018.
  • Its Capital Expenditures stands at $14000.0 for Q4 2018, versus $173000.0 for Q1 2018 and $42000.0 for Q4 2017.